Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).

2.50
Hdl Handle:
http://hdl.handle.net/10541/78151
Title:
Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
Authors:
Fosså, Sophie D; De Wit, Ronald; Roberts, J Trevor; Wilkinson, Peter M; De Mulder, Pieter H M; Mead, Graham M; Cook, Pat; De Prijck, Linda; Stenning, Sally P; Aaronson, N; Bottomley, Andrew; Collette, Laurence
Abstract:
PURPOSE: To describe global quality of life (GLQL) in patients with metastatic testicular cancer (TC) treated with four different schedules of bleomycin, etoposide, and cisplatin (BEP) chemotherapy (four v three cycles given over 5 v 3 days). PATIENTS AND METHODS: Quality-of-life data were prospectively collected in 666 patients with metastatic TC entered into the European Organization for Research and Treatment of Cancer (EORTC) Trial 30941/United Kingdom Medical Research Council Trial TE20, using the EORTC Quality-of-Life Questionnaire C30 and a TC module. Data were analyzed by a mixed effects model and by evaluation of clinically relevant changes at 2 years. RESULTS: The pattern of GLQL changes was similar in the four groups. Two years after chemotherapy, 36% of patients displayed improved GLQL as compared with baseline, whereas GLQL had deteriorated in 13%. At 3 months, patients receiving the 3-day regimen experienced increased gastrointestinal (GI) toxicity more than those receiving the 5-day regimen, with the difference reaching the level of clinical relevance (>or = 10-point change) if four cycles were given. The 3-day schedule increased the 2-year risk of tinnitus, with clinical relevance demonstrated after four cycles. Long-term peripheral neuropathy and Raynaud-like phenomena were not associated with the number of cycles or days per cycle. At 2 years, Raynaud-like phenomena, tinnitus, or reduced hearing were reported by 21% to 26% of the patients. CONCLUSION: Because of the excess of acute GI toxicity and the increased risk of tinnitus after the 3-day regimen, we recommend the 5-day regimen if four cycles of BEP are planned. If only three cycles are to be given, then the 3-day regimen is acceptable, even given the increased risk of nausea/vomiting at 3 months.
Affiliation:
Norwegian Radium Hospital, Oslo, Norway. s.d.fossa@klinmed.uio.no
Citation:
Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). 2003, 21 (6):1107-18 J. Clin. Oncol.
Journal:
Journal of Clinical Oncology
Issue Date:
15-Mar-2003
URI:
http://hdl.handle.net/10541/78151
PubMed ID:
12637478
Type:
Article
Language:
en
ISSN:
0732-183X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorFosså, Sophie D-
dc.contributor.authorDe Wit, Ronald-
dc.contributor.authorRoberts, J Trevor-
dc.contributor.authorWilkinson, Peter M-
dc.contributor.authorDe Mulder, Pieter H M-
dc.contributor.authorMead, Graham M-
dc.contributor.authorCook, Pat-
dc.contributor.authorDe Prijck, Linda-
dc.contributor.authorStenning, Sally P-
dc.contributor.authorAaronson, N-
dc.contributor.authorBottomley, Andrew-
dc.contributor.authorCollette, Laurence-
dc.date.accessioned2009-08-21T11:47:27Z-
dc.date.available2009-08-21T11:47:27Z-
dc.date.issued2003-03-15-
dc.identifier.citationQuality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). 2003, 21 (6):1107-18 J. Clin. Oncol.en
dc.identifier.issn0732-183X-
dc.identifier.pmid12637478-
dc.identifier.urihttp://hdl.handle.net/10541/78151-
dc.description.abstractPURPOSE: To describe global quality of life (GLQL) in patients with metastatic testicular cancer (TC) treated with four different schedules of bleomycin, etoposide, and cisplatin (BEP) chemotherapy (four v three cycles given over 5 v 3 days). PATIENTS AND METHODS: Quality-of-life data were prospectively collected in 666 patients with metastatic TC entered into the European Organization for Research and Treatment of Cancer (EORTC) Trial 30941/United Kingdom Medical Research Council Trial TE20, using the EORTC Quality-of-Life Questionnaire C30 and a TC module. Data were analyzed by a mixed effects model and by evaluation of clinically relevant changes at 2 years. RESULTS: The pattern of GLQL changes was similar in the four groups. Two years after chemotherapy, 36% of patients displayed improved GLQL as compared with baseline, whereas GLQL had deteriorated in 13%. At 3 months, patients receiving the 3-day regimen experienced increased gastrointestinal (GI) toxicity more than those receiving the 5-day regimen, with the difference reaching the level of clinical relevance (>or = 10-point change) if four cycles were given. The 3-day schedule increased the 2-year risk of tinnitus, with clinical relevance demonstrated after four cycles. Long-term peripheral neuropathy and Raynaud-like phenomena were not associated with the number of cycles or days per cycle. At 2 years, Raynaud-like phenomena, tinnitus, or reduced hearing were reported by 21% to 26% of the patients. CONCLUSION: Because of the excess of acute GI toxicity and the increased risk of tinnitus after the 3-day regimen, we recommend the 5-day regimen if four cycles of BEP are planned. If only three cycles are to be given, then the 3-day regimen is acceptable, even given the increased risk of nausea/vomiting at 3 months.en
dc.language.isoenen
dc.subjectTesticular Canceren
dc.subject.meshActivities of Daily Living-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBleomycin-
dc.subject.meshCisplatin-
dc.subject.meshDigestive System-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshEmotions-
dc.subject.meshEtoposide-
dc.subject.meshEurope-
dc.subject.meshGerminoma-
dc.subject.meshHealth Status-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMulticenter Studies as Topic-
dc.subject.meshPrognosis-
dc.subject.meshQuality of Life-
dc.subject.meshQuestionnaires-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshRole-
dc.subject.meshSurvival Analysis-
dc.subject.meshTesticular Neoplasms-
dc.subject.meshTreatment Outcome-
dc.titleQuality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).en
dc.typeArticleen
dc.contributor.departmentNorwegian Radium Hospital, Oslo, Norway. s.d.fossa@klinmed.uio.noen
dc.identifier.journalJournal of Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.